Company profile for Aptevo Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a resul...
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, etc.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2401 4th Avenue, Suite 1050 Seattle, WA 98121
Telephone
Telephone
206-838-0500
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-11-10/aptevo-debuts-first-trispecific-antibody-candidate-apvo451-with-preclinical-data-demonstrating-imm

PHARMIWEB
10 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-06/aptevo-therapeutics-reports-3q25-financial-results-and-provides-a-business-update

PHARMIWEB
06 Nov 2025

https://www.pharmiweb.com/press-release/2025-10-08/aptevo-presenting-scientific-and-clinical-updates-at-sitc-and-ash-also-participating-in-leading-fin

PHARMIWEB
08 Oct 2025

https://www.pharmiweb.com/press-release/2025-09-16/mipletamig-delivers-100-remission-rate-in-cohort-3-of-rainier-trial-for-aml

PHARMAWEB
16 Sep 2025

https://www.pharmiweb.com/press-release/2025-08-13/aptevo-highlights-apvo442-a-cd3-directed-preclinical-candidate-for-prostate-cancer

PHARMAWEB
13 Aug 2025

https://www.pharmiweb.com/press-release/2025-08-11/aptevo-therapeutics-reports-2q25-financial-results-and-provides-a-business-update

PHARMAWEB
11 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty